COMPASS Pathways plc (CMPS) Stock Score, Valuation & Financial Research

COMPASS Pathways plc is in the Healthcare sector and Biotechnology industry. It is reviewed using Wall Street Score's company-strength, valuation, growth and financial-health framework. A complete Wall Street Score is not currently available.

Quick answer for CMPS

COMPASS Pathways plc does not currently have a complete Wall Street Score. The stored market price is USD 12.44. These figures are a research snapshot, not a buy or sell recommendation.

What COMPASS Pathways plc does

COMPASS Pathways plc is a mental healthcare company with a primary presence in the United Kingdom and the United States. Established in 2020 and headquartered in London, UK, the firm focuses on developing novel treatments. Its key product is COMP360, an investigational psilocybin therapy. This therapy has advanced through Phase IIb clinical trials for treatment-resistant depression and is currently undergoing Phase II trials for post-traumatic stress disorder. The company previously operated under the name COMPASS Rx Limited before rebranding to COMPASS Pathways plc in August 2020.

Company business and revenue

Research reporting period: 2025-12-31. A research update is not a new financial filing.

How the company makes money

Compass Pathways is a clinical-stage biotechnology company that does not yet generate commercial revenue. Its business model focuses on the research, development, and potential future commercialization of proprietary mental health therapies, specifically COMP360 psilocybin, which requires significant capital investment in clinical trials and regulatory approval processes.

Products and services

  • The company's primary product candidate is COMP360, a proprietary, synthetic psilocybin formulation currently in clinical development for treatment-resistant depression and other mental health conditions.

Brands and product families

  • COMP360 — Proprietary, investigational, synthetic psilocybin formulation. Source

Customer types

Healthcare providers and patients with treatment-resistant depression.

Suppliers, materials and equipment

  • Contract Manufacturing Organizations — The company relies on third-party contract manufacturing organizations for the production of its investigational drug product, COMP360. Source

Competitors and product-market comparisons

  • Pharmaceutical and biotechnology companies — Companies developing traditional antidepressants, other psychedelic-based therapies, or alternative treatments for mental health conditions. Source

Business strengths to evaluate

  • Proprietary COMP360 psilocybin formulation and clinical trial progress Source

Business risks and research considerations

  • History of operating losses and dependence on additional financing Source
  • Uncertainty of clinical trial outcomes and regulatory approval Source

Sources: Company research source

Company research refreshed 2026-10-12. This is saved research, not a live check of company relationships. Check the reporting period and source disclosures. Financial figures and scores follow their separate update schedules.

CMPS financial snapshot

Statement amounts: USD. Quote amounts: USD. No exchange-rate conversion is performed in this snapshot. Market-capitalization currency is not supplied by this projection.

Wall Street Score:
Not currently available
Stored price:
USD 12.44
Market capitalization:
1.68B (currency not supplied)
Revenue:
USD 0.00
Net income:
USD -394.19M
Free cash flow:
USD -157.24M
Cash:
USD 433.3M
Total debt:
USD 54.63M
EPS:
USD -5.57

What stands out

  • Free cash flow is USD -157.24M, negative for the stored period.
  • The balance sheet shows USD 433.3M of cash versus USD 54.63M of total debt, an excess of cash over debt on these two reported measures.
  • The current research record carries a fundamental change risk warning, which should be reviewed alongside the score.

Company-specific financial comparisons

The following are calculated from saved company data, not forecasts or statements about future performance. Differences in reporting dates or units can make a ratio misleading; verify the original filings.

  • Cash exceeds debt by USD 378.67M using the stored balance-sheet values. This does not include other obligations or restricted cash.

Questions worth answering for CMPS

Use these questions to check the stored figures against the latest company filings. They identify issues to investigate; they are not findings about management's plans or future results.

  • How long can CMPS fund negative free cash flow using its current cash position before it may need more debt or new shares?
  • How is CMPS likely to use its cash advantage: reinvestment, acquisitions, debt reduction, dividends or buybacks?
  • What specifically needs to improve for CMPS to reach sustainable profitability?
  • What does the current fundamental change risk warning mean for the reliability or interpretation of CMPS's score?

What the numbers mean

A complete valuation score is not currently available, so valuation should be checked using the available earnings, cash-flow and price data.

A complete financial score is not currently available, so investors should review cash, debt, earnings and cash flow directly.

A strong company and an attractive stock price are not always the same thing. Revenue, earnings, free cash flow, debt, management quality, competitive advantage and valuation should be considered together. Wall Street Score organizes these inputs into a consistent research framework so investors can identify what deserves deeper review.

Data freshness: Financial data last refreshed 2026-10-01.

Research-input completeness: 64% of the scoring inputs required for this public page are currently available.

How to research CMPS

Start by understanding how the company makes money. Then compare revenue and earnings trends, cash generation, debt, liquidity and valuation. Review the company's latest filings and earnings reports before acting on any score or model estimate.

Learn how to analyze a stock · Read the Wall Street Score methodology · Browse other stocks

Data may change as company filings and market prices update. Educational research only; not a buy or sell recommendation.